WOCKPHARMA2024-07-012024-09-30 WOCKPHARMA2024-07-012024-09-30 WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2024-09-30 WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2024-04-01 2025-03-31 2024-11-13 2024-11-08 INR Crores Half yearly 11:25:00 13:20:00 2024-11-13 2024-11-13 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2024-07-01 2024-09-30 Unaudited Standalone 3700000000.00 110000000.00 3810000000.00 880000000.00 510000000.00 -10000000.00 650000000.00 530000000.00 430000000.00 1180000000.00 4170000000.00 -360000000.00 0.00 -360000000.00 0.00 0.00 0.00 0.00 -360000000.00 0.00 0.00 0.00 0.00 -360000000.00 0.00 -360000000.00 0.00 0.00 770000000.00 5 -2.34 -2.34 0.00 0.00 -2.34 -2.34 0.00 0.00 0.00 Notes To Standalone Results :- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 13, 2024. The results have been subjected to limited review by the Statutory Auditors of the Company. 2)During the quarter ended September 30, 2024 , the Company has allotted 8,610 ( Year to date: 8,610) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 3)Further to the approval of the Board of Directors and Shareholders at their meetings , the Company has, on November 11, 2024, alloted 9,049,773 Equity Shares of Rs. 5/- each to successful Qualified Institutional Buyers at the issue price of Rs.1,105/- per share, aggregating to approximately Rs. 1,000 crore. 4)The Company is exclusively into Pharmaceutical business segment. 5) The amount Rs (0.26) Crores stated under OCI- Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset) is not considered due to rounding off purpose. Single segment 2024-04-01 2024-09-30 Unaudited Standalone 7220000000.00 370000000.00 7590000000.00 1700000000.00 820000000.00 130000000.00 1270000000.00 1110000000.00 860000000.00 2000000000.00 7890000000.00 -300000000.00 0.00 -300000000.00 0.00 0.00 0.00 0.00 -300000000.00 0.00 0.00 0.00 0.00 -300000000.00 -10000000.00 -310000000.00 0.00 0.00 770000000.00 5 -1.96 -1.96 0.00 0.00 -1.96 -1.96 0.00 0.00 0.00 Other Expenses 1180000000.00 Other Expenses 2000000000.00 13120000000.00 690000000.00 0.00 0.00 450000000.00 9560000000.00 0.00 0.00 2970000000.00 0.00 0.00 650000000.00 3620000000.00 2500000000.00 1790000000.00 31730000000.00 3180000000.00 480000000.00 7070000000.00 500000000.00 290000000.00 0.00 980000000.00 9320000000.00 0.00 2140000000.00 14640000000.00 1040000000.00 0.00 47410000000.00 770000000.00 16880000000.00 17650000000.00 17650000000.00 9250000000.00 0.00 2210000000.00 11460000000.00 300000000.00 0.00 0.00 0.00 11760000000.00 8470000000.00 5330000000.00 2780000000.00 16580000000.00 1130000000.00 270000000.00 20000000.00 0.00 18000000000.00 0.00 0.00 29760000000.00 47410000000.00 Notes to Assets Liabilities: 1. Property, Plant and Equipment of Rs. 1312 crore includes Right of use assets amounting to Rs. 283 crore. 2. Non-current Investment also includes Investments in subsidiaries amounting to Rs. 0.45 crore 3. Other non-current assets of Rs. 179 includes Non-current tax assets (net) amounting to Rs. 75 crore. 4. Other non-current financial liabilities consists Lease liabilities amounting to Rs. 221 crore. 5. Trade payables (current) of Rs. 533 crore, current consists of (a) Total outstanding dues of Micro enterprises and Small enterprises amounting to Rs. 25 crore and (b) Total outstanding dues of creditors other than micro enterprises and small enterprises amounting to Rs. 508 crore. 6. Other current financial liabilities of Rs. 278 crores include Lease liabilities amounting to Rs. 73 crore. 7. Non-current assets classified as held for sale represents Assets classified as held for sale. Please also, additionally refer to the Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2024 as attached to the Outcome of Board Meeting Notes to Cash Flow Statements: 1. The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'. 2. Repayment of lease liabilities consists of: Payment of interest Rs. 14 crore (Previous period - Rs. 18 crore) Payment of Principal Rs. 24 crore (Previous period - Rs. 23 crore) 3. Figures in bracket indicate cash outflow. 4. For Reconciliation of cash and cash equivalents as per the cash flow statement refer to the Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2024 as attached to the Outcome of Board Meeting. 5.Adjustments for unrealised foreign exchange losses gains consists of Net foreign exchange fluctuation (gain)/Loss, net. 6.Other adjustments for non-cash items includes (Reversal of )/Allowance for expected credit loss, doubtful advances and bad debts of Rs. 11 Cr, liabilities no longer required written back Rs. 23 Cr , Fair valuation impact on investments Rs.1 Cr and Gain on sale of investments Rs. 4 Crore. 7.Adjustments for decrease (increase) in other current assets consists of Loans and Advances and other assets. 8.Adjustments for increase (decrease) in other current liabilities consists of Liabilities and provisions. 9. Cash inflow (outflow) of cash consists of Purchase of current investments, Sale of current investments (321 Cr), Purchase of current investments Rs 365 Cr and Margin money under lien and Bank balances (other than cash and cash equilvalents) Rs. 6 Crore and Guarantee commission received( Rs 24 Crore). 10.Proceeds from sales of property, plant and equipment includes assets held for sale. 11.Purchase of property, plant and equipment includes purchase of property, plant and equipment and capital work-in progress. 12.Purchase of intangible assets under development includes purchase of Intangible assets and Intangible assets under development. 13.Proceeds from issuance of shares consists of transaction cost relating to Right Issue/ QIP of Rs. 2 Crore including proceeds from Issuance of Equity share capital under ESOS Rs. 0.004 crore. 14.Proceeds from borrowing consists of loan from Related Parties of Rs. 47 Crore. 15. Repayment from borrowing consists of Repayment of long term borrowings Rs. 97 Crore , Repayment of loan taken from Related Parties long term Rs. 4 Crore , Repayment of loan taken from Related Parties Short term 13 crore and short term borrowing(net ) Rs 3 crore . 16.Aggregated/ segreggated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. Please also, additionally refer to the Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2024 as attached to the Outcome of Board Meeting 1110000000.00 30000000.00 -1300000000.00 0.00 -320000000.00 0.00 0.00 0.00 0.00 -480000000.00 0.00 -100000000.00 0.00 860000000.00 0.00 0.00 0.00 0.00 0.00 -60000000.00 0.00 50000000.00 0.00 0.00 0.00 0.00 0.00 -390000000.00 0.00 -700000000.00 -1000000000.00 0.00 0.00 0.00 -270000000.00 0.00 -730000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 70000000.00 240000000.00 0.00 0.00 0.00 1440000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -250000000.00 0.00 -1860000000.00 0.00 0.00 -20000000.00 0.00 0.00 0.00 0.00 0.00 470000000.00 1110000000.00 0.00 380000000.00 0.00 500000000.00 0.00 0.00 -1540000000.00 -4130000000.00 0.00 -4130000000.00 4630000000.00 500000000.00 i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset) -2600000.00 i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset) -10000000.00 -2600000.00 -10000000.00 0.00 0.00 Roundoff 2600000.00 Roundoff 0.00 2600000.00 0.00 0.00 0.00